Tevogen Bio Holdings (TVGN) Cash from Financing Activities (2023 - 2026)

Tevogen Bio Holdings has reported Cash from Financing Activities for 4 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 28.16% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (down 23.65% YoY), and the FY2025 full-year result was $11.7 million, down 4.64% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $2.9 million, up from $1.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $5.0 million in Q3 2024, with the low at $422250.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $2.6 million across 4 years, with a median of $2.5 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 426.32% — and 2025, when it slumped 32.14%.
• Tevogen Bio Holdings' Cash from Financing Activities stood at $422250.0 in 2023, then surged by 373.65% to $2.0 million in 2024, then decreased by 11.95% to $1.8 million in 2025, then surged by 63.19% to $2.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $2.9 million (Q1 2026), $1.8 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.